BioSpace News Archive

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced that ProFound AI® Version 3.0 for Digital Breast Tomosynthesis received CE Mark approval.

BioCardia®, Inc., a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, announced it is to join the Russell Microcap® Index.

XWPharma Ltd. today announced that XW10172, an internally discovered, novel, patented conjugate of the GABAB agonist oxybate, demonstrated in Phase 1 clinical trials multiple features that support development for treatment for various sleep disorders.

eFFECTOR Therapeutics, Inc. (“eFFECTOR”), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, and Chris Ehrlich, chief executive officer and director of Locust Walk Acquisition Corp. (NASDAQ: LWAC)

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will present five abstracts highlighting data from the company’s chronic hepatitis B (CHB) therapeutic programs

RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy

Vir Biotechnology, Inc. announced that four abstracts highlighting data from its hepatitis B clinical program have been accepted for two oral and two poster presentations at the European Association for the Study of the Liver Digital International Liver Congress taking place virtually from June 23-26, 2021.

Roche Diabetes Care Canada is pleased to announce that it has received a Health Canada authorization for the Accu-Chek Guide Link blood glucose meter, the latest innovation from Roche Diabetes Care to help Canadians living with type-1 diabetes manage their health and worry less about daily therapy routines.

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug Application (“IND”) to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154,

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn, will participate in the AGP Summer Healthcare Symposium